Aurinia Pharmaceuticals (AUPH) Tops Q4 EPS by 9c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 EPS of ($0.18), $0.09 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $28.4 million versus the consensus estimate of $27.42 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• UBS sees a negative catalyst ahead for Nike: Here’s what to watch
• Surgery Partners sells Idaho Falls facilities to Intermountain Health for $797M
• Faraday Future says it regained Nasdaq compliance after equity shortfall